Emerging data suggest Retatru tide , a dual agonist targeting both incretin and GIP , may provide a significant step forward for obesity loss . Initial clinical investigations have indicated considerable reductions in visceral tissue, possibly outperforming current weight-loss treatments. However , more study is required to thoroughly determine its